Assessment for the image interpretation of 111In-ibritumomab tiuxetan in the phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma

Kakuigaku

Volumn 45, Issue 2, 2008, Pages 99-113

  Oriuchi, Noboru ^a   Koizumi, Kiyoshi ^b   Koizumi, Mitsuru ^c   Terui, Shoji ^d,e   Yamaura, Hidekazu ^f   Imai, Yutaka ^g   Kaneta, Tomohiro ^h   Nawano, Shigeru ^i,j   Kubo, Atsushi ^k   Nishimura, Tsunehiko ^l   Kinuya, Seigo ^m   Tobinai, Kensei ^d   Endo, Keigo ^a  

^a GUNMA UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c National Institute of Radiological Sciences

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e Association of Health and Welfare of Nagano Agricultural Cooperatives   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g TOKAI UNIVERSITY HOSPITAL   (Japan)

^h TOHOKU UNIVERSITY HOSPITAL   (Japan)

ⁱ NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^j International University of Health and Welfare Mita Hospital

^k KEIO UNIVERSITY   (Japan)

^l KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^m KANAZAWA UNIVERSITY   (Japan)

more..

Author keywords

111In ibritumomab tiuxetan; 90Y ibritumomab tiuxetan; Non Hodgkin's lymphoma; Radio immunotherapy; Zevalin

Indexed keywords

DIAGNOSTIC AGENT; IBRITUMOMAB TIUXETAN; INDIUM; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RADIOIMMUNOTHERAPY; RECURRENT DISEASE; SCINTISCANNING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HUMANS; INDIUM; INDIUM RADIOISOTOPES; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RECURRENCE;

EID: 47649095086     PISSN: 00227854     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Morgan G, Vornanen M, Puitinen J, Naukkarinen A, Brincker H, Olsen J, et al: Changing trends in the incidence of non-Hodgkin's lymphoma in Europe. Ann Oncol 1997; 8 (Suppl 2): S49-S54.
2. Weisenburger DD: Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic. Ann Oncol 1994; 5 (Suppl 1): sl9-s24.
3. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64.
4. Japanese source
5. Lymphoma Study Group of Japanese Pathologists: The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int 2000; 50: 696-702.
6. Japanese source
7. Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, et al: Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470-1480.
8. Garvin AJ, Simon RM, Osborne CK, Merrill J, Young RC, Berard CW: An autopsy study of histologic progression in non-Hodgkin's lymphomas: 192 cases from the National Cancer Institute. Cancer 1983; 52: 393-398.
9. Acker B, Hoppe RT, Colby TV, Cox RS, Kaplan HS, Rosenberg SA: Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol 1983; 1: 11-16.
10. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiane M: Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1861.
11. Longo DL: What's the deal with follicular lymphomas? J Clin Oncol 1993; 11: 202-208.
12. Paryani SB, Hoppe RT, Cox RS, Colby TV, Rosenberg SA, Kaplan HS: Analysis of non-Hodgkin's lymphomas with nodular and favorable histologies, stages I and II. Cancer 1983; 52: 2300-2307.
13. McLaughlin P, Fuller LM, Velasquez WS, Sullivan-Halley JA, Butler JJ, Cabanillas F: Stage I-II follicular lymphoma: treatment results for 76 patients. Cancer 1986; 58: 1596-1602.
14. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
15. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711-4716.
16. Ogura M, Morishima Y, Kagami Y, Watanabe T, Itoh K, Igarashi T, et al: Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci 2006; 97: 305-312.
17. Anderson WT, Strand M: Radiolabeled antibody: iodine versus radiometal chelates. NCI Monogr 1987; 3: 149-151.
18. Berger MJ: Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. J Nucl Med 1971; March (Suppl 5): 5-23.
19. Zelenetz AD: Radioimmunotherapy for lymphoma. Curr Opin Oncol 1999; 11: 375-380.
20. Prestwich WV, Nunes J, Kwok CS: Beta dose point kernels for radionuclides of potential use in radioimmunotherapy. J Nucl Med 1989; 30: 1036-1046.
21. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-3803.
22. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, et al: Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336-4342.
23. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262-3269.
24. Witzig TE, Gordon LI, Cabanillas F, Czuczuman MS, Emmanouilides C, Joyce R, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463.
25. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, et al: Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20 B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103: 4429-4431.
26. 90Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma. Cancer Sci 2005; 96: 903-910.
27. 90Y Ibritumomab tiuxetan (Y2B8, Zevalin®) radioimmunotherapy is highly effective for patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma pretreated with Rituximab-containing chemotherapy (R-Chemo): Japanese Multicenter Phase II Study. Blood 2006; 108. (abstract)
28. 90Y-labeled 1 B4M-DTPA antiTac monoclonal antibody distribution. J Nucl Med 1999; 40: 268-276.
29. 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 1999; 15: 1017-1025.
30. Gansow OA: Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Int J Rad Appl Insrum Part B 1991; 18 (4): 369-381.
31. Zevalin (ibritumomab tiuxetan) [package insert]. San Diego, CA: Biogen Idec Inc; 2005.
32. 90Y- Ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003; 44: 465-474.
33. Conti PS, White C, Pieslor P, Molina A, Aussie J, Foster P: The role of imaging with (111)Inibritumomab tiuxetan in the ibritumomab tiuxetan (Zevalin) regimen: results from a Zevalin Imaging Registry. J Nucl Med 2005; 46: 1812-1818.